Page last updated: 2024-09-05

tolvaptan and Body Weight

tolvaptan has been researched along with Body Weight in 43 studies

Research

Studies (43)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (9.30)29.6817
2010's29 (67.44)24.3611
2020's10 (23.26)2.80

Authors

AuthorsStudies
Kim, S; Kurita, Y; Sato, N; Uno, S1
de la Rosa, RE; García, AIM; García, EM; Moyano, AP; Oporto, FR; Utiel, FJB1
Iida, H; Kaida, S; Maehira, H; Maekawa, T; Miyake, T; Mori, H; Nitta, N; Takebayashi, K; Tani, M1
Amitani, K; Iha, H; Imura, H; Ishihara, S; Ishikawa, M; Ishizuka, A; Ito, Y; Kikuchi, A; Kobayashi, N; Maruyama, Y; Mitsuishi, T; Nakama, K; Nakamura, S; Nohara, T; Ohkuma, S; Omote, T; Sato, N; Shigihara, S; Shimizu, W; Sone, M; Takagi, K; Takahashi, N; Tokuyama, H; Yamamoto, E1
Kojima, Y; Kudo, T; Murai, Y; Satoh, T; Uehara, K1
Kanai, A; Kobayashi, T; Kojima, T; Sumitomo, N; Yoshiba, S1
Horie, S; Ibuki, T; Kawano, H; Muto, S; Nakajima, K; Okada, T; Shibasaki, Y1
Mori, T; Shinoda, R; Shinoda, Y; Yoshimura, T1
Enomoto, N; Gotou, T; Hayashi, T; Higuchi, M; Itakura, J; Izumi, N; Komiyama, Y; Kubota, Y; Kurosaki, M; Nakanishi, H; Oh, W; Okada, M; Takada, H; Takahashi, Y; Takaura, K; Tamaki, N; Yasui, Y1
Goya, T; Kato, M; Kohjima, M; Kotoh, K; Masumoto, A; Miyazaki, M; Motomura, K; Senjyu, T; Tanaka, K; Yada, M1
Egashira, H; Hidaka, H; Ichita, C; Kako, M; Koizumi, K; Masuda, S; Nakayama, T; Sasaki, A; Sung, JH; Tokoro, S; Uojima, H1
Fei, YH; Han, XB; Liu, YH; Xu, HT1
Chen, CW; Chen, YX; Cheng, J; Ding, HG; Han, T; Mao, Q; Mao, YM; Niu, JQ; Tang, JT; Wang, MR; Wang, YF; Wang, ZH; Wei, Z; Xie, Q; Yang, YP; Ye, WJ; Zeng, M1
Fujiwara, Y; Harada, S; Kishimoto, S; Kishimoto, Y; Kurashiki, T; Nakamura, Y; Nishimura, M; Onohara, T1
Choi, HY; Ha, SK; Han, SW; Jeong, KH; Kang, KP; Kim, GH; Kim, HJ; Kim, HY; Kim, SW; Kim, YW; Shin, SK; Yi, JH1
Kodama, K; Kogiso, T; Sagawa, T; Taniai, M; Tokushige, K1
Dittrich, S; Habash, S; Kerling, A; Moosmann, J; Müller, H; Rüffer, A; Toka, O; Weiss, C1
Gao, WQ; Meng, XD; Sun, Z1
Akamatsu, N; Arita, J; Hasegawa, K; Ishizawa, T; Kaneko, J; Kiritani, S; Kokudo, N; Matsumura, M; Miyata, Y; Tamura, S1
Hidaka, H; Kako, M; Koizumi, W; Kubota, K; Nakazawa, T; Shibuya, A; Sung, JH; Tanaka, Y; Uojima, H; Wada, N1
Bellos, I; Kontzoglou, K; Perrea, DN1
Kobayashi, T; Komatsu, M; Komorizono, Y; Okada, M; Okita, K; Sakai, T; Sakaida, I; Yamashita, S1
Cao, Y; Deng, S; Huang, J; Huang, Y; Qian, J; Rong, S; Tan, J; Wang, C; Xiong, B; Yao, Y; Zou, Y1
Inukai, S; Ito, K; Kato, T; Nagasaki, R; Saitoh, S; Sato, N; Sugiura, T; Suzuki, K1
Adachi, O; Akiyama, M; Fujiwara, H; Kanda, K; Katahira, S; Kawamoto, S; Kawatsu, S; Kumagai, K; Saiki, Y; Sakatsume, K; Suzuki, T; Takahara, S1
Al-Mohammad, A; Alskaf, E; Tridente, A1
Nakajima, K; Sakaida, I; Shibasaki, Y; Tachikawa, S; Terai, S; Tsubouchi, H1
Iwahasi, T; Iwahori, A; Iwasaki, T; Koizumi, N; Maruno, K; Matsuyama, K; Nishibe, T; Ogino, H; Takahashi, S; Toguchi, K1
Doi, A; Hanatani, A; Iwata, S; Kitada, R; Matsumura, Y; Shibata, A; Sugioka, K; Takagi, M; Yoshiyama, M1
Hori, H; Kono, T; Tanaka, H; Tayama, E; Ueda, T; Yamaki, Y1
Chayama, K; Kaneko, A; Kato, M; Murawaki, Y; Okada, M; Okita, K; Ono, N; Sakaida, I; Sata, M; Yoshihara, H; Yoshihara, N1
Asanoi, H; Hori, M; Izumi, T; Matsuzaki, M; Tsutamoto, T1
Fukunami, M; Hori, M; Izumi, T; Matsuzaki, M2
Fujiki, H; Nakamura, S; Nakayama, S; Onogawa, T; Sakamoto, Y; Yamamura, Y1
Hirayama, A; Hori, M; Inomata, T; Izumi, T; Matsuzaki, M1
Bilsker, M; Hauptman, PJ; Konstam, MA; O'Brien, T; Orlandi, C; Sequeira, R; Thomas, I; Udelson, JE; Zimmer, C1
Bai, H; Li, L; Zhu, WL1
Dohi, K; Hoshino, K; Ichikawa, K; Ito, M; Kumagai, N; Machida, H; Nakajima, H; Nakamori, S; Nakamura, M; Nobori, T; Okamoto, S; Onishi, K; Sato, Y; Sugimoto, T; Sugiura, E; Watanabe, K; Yamada, T1
Czerwiec, F; Gheorghiade, M; Kambayashi, J; Niazi, I; Orlandi, C; Ouyang, J; Zampino, M1
Burnett, JC; Demets, D; Gheorghiade, M; Grinfeld, L; Konstam, MA; Maggioni, A; Orlandi, C; Swedberg, K; Udelson, JE; Zannad, F; Zimmer, C1
Burnett, JC; Cook, T; Gheorghiade, M; Grinfeld, L; Konstam, MA; Maggioni, AP; Orlandi, C; Ouyang, J; Swedberg, K; Udelson, JE; Zannad, F; Zimmer, C1
Aizawa, Y; Kodama, M; Ma, M; Palaniyandi, SS; Veeraveedu, PT; Watanabe, K; Yamaguchi, K1

Reviews

4 review(s) available for tolvaptan and Body Weight

ArticleYear
Efficacy of tolvaptan for chronic heart failure: Study protocol for a systematic review of randomized controlled trial.
    Medicine, 2019, Volume: 98, Issue:7

    Topics: Antidiuretic Hormone Receptor Antagonists; Body Weight; Chronic Disease; Heart Failure; Humans; Quality of Life; Randomized Controlled Trials as Topic; Research Design; Sodium; Tolvaptan; Urine

2019
Predictors of tolvaptan short-term response in patients with refractory ascites: A meta-analysis.
    Journal of gastroenterology and hepatology, 2020, Volume: 35, Issue:2

    Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Blood Urea Nitrogen; Body Weight; C-Reactive Protein; Forecasting; Hepatitis C; Humans; Time Factors; Tolvaptan

2020
The short-term and long-term effects of tolvaptan in patients with heart failure: a meta-analysis of randomized controlled trials.
    Heart failure reviews, 2015, Volume: 20, Issue:6

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Creatinine; Heart Failure; Humans; Hyponatremia; Potassium; Randomized Controlled Trials as Topic; Sodium; Time Factors; Tolvaptan

2015
Tolvaptan for Heart Failure, Systematic Review and Meta-Analysis of Trials.
    Journal of cardiovascular pharmacology, 2016, Volume: 68, Issue:3

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Heart Failure; Humans; Mortality; Randomized Controlled Trials as Topic; Tolvaptan

2016

Trials

23 trial(s) available for tolvaptan and Body Weight

ArticleYear
Efficacy and safety of intravenous OPC-61815 compared with oral tolvaptan in patients with congestive heart failure.
    ESC heart failure, 2022, Volume: 9, Issue:5

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Diuretics; Female; Heart Failure; Humans; Hyperkalemia; Male; Tolvaptan

2022
Differences in pharmacological property between combined therapy of the vasopressin V2-receptor antagonist tolvaptan plus furosemide and monotherapy of furosemide in patients with hospitalized heart failure.
    Journal of cardiology, 2020, Volume: 76, Issue:5

    Topics: Aged; Aged, 80 and over; Antidiuretic Agents; Antidiuretic Hormone Receptor Antagonists; Blood Pressure; Body Weight; Drug Therapy, Combination; Echocardiography; Female; Furosemide; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Tolvaptan

2020
Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study.
    Japanese journal of clinical oncology, 2021, Mar-03, Volume: 51, Issue:3

    Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Body Weight; Female; Humans; Male; Tolvaptan; Treatment Outcome

2021
Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
    Clinical and experimental nephrology, 2021, Volume: 25, Issue:5

    Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Body Height; Body Mass Index; Body Weight; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Organ Size; Osmolar Concentration; Polycystic Kidney, Autosomal Dominant; Sex Factors; Tolvaptan; Urine

2021
Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study.
    World journal of gastroenterology, 2017, Dec-07, Volume: 23, Issue:45

    Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weight; Diuretics; Drug Therapy, Combination; Female; Furosemide; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Tolvaptan; Treatment Outcome

2017
Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial.
    Journal of digestive diseases, 2018, Volume: 19, Issue:3

    Topics: Abdomen; Adolescent; Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weight; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Sodium; Tolvaptan; Urine; Young Adult

2018
Can Tolvaptan Protect Renal Function in the Early Postoperative Period of Cardiac Surgery? - Results of a Single-Center Randomized Controlled Study.
    Circulation journal : official journal of the Japanese Circulation Society, 2018, 03-23, Volume: 82, Issue:4

    Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Body Weight; Cardiac Surgical Procedures; Creatinine; Diuretics; Drug Therapy, Combination; Female; Humans; Kidney; Male; Middle Aged; Postoperative Period; Tolvaptan

2018
A selective oral vasopressin V2-receptor antagonist for patients with end-stage liver disease awaiting liver transplantation: a preliminary study.
    Bioscience trends, 2019, May-12, Volume: 13, Issue:2

    Topics: Administration, Oral; Adult; Alanine Transaminase; Aspartate Aminotransferases; Body Weight; Creatinine; Diuretics; End Stage Liver Disease; Female; Humans; Liver Transplantation; Male; Middle Aged; Receptors, Vasopressin; Sodium; Tolvaptan

2019
Furosemide Dose Changes Associated with Furosemide/Tolvaptan Combination Therapy in Patients with Cirrhosis.
    Digestive diseases (Basel, Switzerland), 2020, Volume: 38, Issue:1

    Topics: Aged; Aged, 80 and over; Ascites; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Furosemide; Glomerular Filtration Rate; Humans; Japan; Liver Cirrhosis; Male; Middle Aged; Tolvaptan

2020
Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema.
    The Journal of international medical research, 2013, Volume: 41, Issue:3

    Topics: Aged; Ascites; Benzazepines; Body Weight; Diuretics; Drug Administration Schedule; Edema; Female; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Protective Agents; Sodium; Tolvaptan; Treatment Outcome

2013
Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis.
    Journal of gastroenterology, 2017, Volume: 52, Issue:2

    Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Blood Urea Nitrogen; Body Weight; Female; Humans; Japan; Liver Cirrhosis; Male; Middle Aged; Predictive Value of Tests; Tolvaptan; Urine

2017
Effects of short-term administration of tolvaptan after open heart surgery.
    International journal of cardiology, 2016, Oct-01, Volume: 220

    Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Cardiac Surgical Procedures; Diuretics; Drug Monitoring; Drug Therapy, Combination; Female; Fluid Shifts; Furosemide; Humans; Male; Middle Aged; Postoperative Complications; Spironolactone; Tolvaptan; Treatment Outcome; Urinalysis

2016
Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction.
    Heart and vessels, 2017, Volume: 32, Issue:3

    Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Creatinine; Female; Heart Failure; Humans; Japan; Kidney; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Sodium; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan

2017
A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis.
    Journal of gastroenterology, 2010, Volume: 45, Issue:9

    Topics: Administration, Oral; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weight; Dose-Response Relationship, Drug; Edema; Female; Furosemide; Humans; Japan; Liver Cirrhosis; Lower Extremity; Male; Middle Aged; Tolvaptan; Treatment Outcome; Waist Circumference

2010
Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Cardiovascular drugs and therapy, 2011, Volume: 25 Suppl 1

    Topics: Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Asian People; Benzazepines; Body Weight; Diuretics; Double-Blind Method; Drug Therapy, Combination; Edema, Cardiac; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Potassium; Sodium; Tolvaptan; Young Adult

2011
Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).
    Cardiovascular drugs and therapy, 2011, Volume: 25 Suppl 1

    Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Body Weight; Diuretics; Double-Blind Method; Edema, Cardiac; Female; Heart Failure; Humans; Male; Middle Aged; Potassium; Sodium; Tolvaptan

2011
Efficacy and safety of tolvaptan in heart failure patients with sustained volume overload despite the use of conventional diuretics: a phase III open-label study.
    Cardiovascular drugs and therapy, 2011, Volume: 25 Suppl 1

    Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Asian People; Benzazepines; Blood Urea Nitrogen; Body Weight; Creatinine; Diuretics; Edema, Cardiac; Female; Heart Failure; Humans; Male; Potassium; Sodium; Tolvaptan

2011
Phase III clinical pharmacology study of tolvaptan.
    Cardiovascular drugs and therapy, 2011, Volume: 25 Suppl 1

    Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Asian People; Benzazepines; Body Weight; Calcium; Creatinine; Diuretics; Double-Blind Method; Drug Therapy, Combination; Edema, Cardiac; Female; Furosemide; Humans; Magnesium; Male; Middle Aged; Potassium; Sodium; Tolvaptan; Uric Acid

2011
A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.
    Journal of cardiac failure, 2011, Volume: 17, Issue:12

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Furosemide; Heart Failure, Systolic; Humans; Male; Middle Aged; Statistics as Topic; Stroke Volume; Tolvaptan; Vasopressins; Ventricular Function, Left

2011
[The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia].
    Zhonghua xin xue guan bing za zhi, 2011, Volume: 39, Issue:10

    Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Pressure; Body Weight; Double-Blind Method; Heart Failure; Humans; Hyponatremia; Sodium; Tolvaptan

2011
Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
    Circulation, 2003, Jun-03, Volume: 107, Issue:21

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Body Weight; Chronic Disease; Diuretics; Double-Blind Method; Edema, Cardiac; Female; Furosemide; Heart Failure; Humans; Hyponatremia; Male; Middle Aged; Osmolar Concentration; Sodium; Tolvaptan; Treatment Outcome; Urinalysis; Water-Electrolyte Balance

2003
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).
    Journal of cardiac failure, 2005, Volume: 11, Issue:4

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Double-Blind Method; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypokalemia; Placebos; Quality of Life; Research Design; Stroke Volume; Survival Rate; Tolvaptan; Treatment Outcome; Urination; Ventricular Dysfunction, Left

2005
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
    JAMA, 2007, Mar-28, Volume: 297, Issue:12

    Topics: Administration, Oral; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Urea Nitrogen; Body Weight; Cardiovascular Agents; Creatinine; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Quality of Life; Sodium; Tolvaptan

2007

Other Studies

16 other study(ies) available for tolvaptan and Body Weight

ArticleYear
Identifying the main predictors of urine output in autosomal-dominant polycystic kidney disease (ADPKD) patients taking tolvaptan.
    International urology and nephrology, 2023, Volume: 55, Issue:10

    Topics: Antidiuretic Hormone Receptor Antagonists; Body Weight; Creatinine; Glomerular Filtration Rate; Humans; Kidney; Male; Polycystic Kidney, Autosomal Dominant; Tolvaptan

2023
Effect of early administration of tolvaptan on pleural effusion post-hepatectomy.
    Langenbeck's archives of surgery, 2023, Oct-16, Volume: 408, Issue:1

    Topics: Body Weight; Hepatectomy; Humans; Pleural Effusion; Risk Factors; Tolvaptan

2023
Efficacy and safety of tolvaptan after pediatric congenital heart disease surgery.
    Heart and vessels, 2021, Volume: 36, Issue:5

    Topics: Antidiuretic Hormone Receptor Antagonists; Body Weight; Cardiac Surgical Procedures; Female; Heart Defects, Congenital; Humans; Infant; Male; Postoperative Complications; Retrospective Studies; Tolvaptan; Treatment Outcome

2021
[Retrospective Observational Study on Predictors of Body Weight and BNP Teduction in Cases of Tolvaptan Induction for Heart Failure].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2021, Volume: 141, Issue:2

    Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Body Weight; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Retrospective Studies; ROC Curve; Sodium; Tolvaptan

2021
Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio.
    PloS one, 2017, Volume: 12, Issue:3

    Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weight; Diuretics; Female; Humans; Hyponatremia; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Potassium; Sodium; Tolvaptan; Treatment Outcome; Weight Loss

2017
Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma.
    World journal of gastroenterology, 2017, Aug-07, Volume: 23, Issue:29

    Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weight; Carcinoma, Hepatocellular; Disease Progression; Diuretics; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Female; Furosemide; Humans; Liver; Liver Failure; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Spironolactone; Tolvaptan; Treatment Outcome

2017
Long-term low-dose tolvaptan treatment in hospitalized male patients aged >90 years with hyponatremia: Report on safety and effectiveness.
    Medicine, 2017, Volume: 96, Issue:52

    Topics: Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Chlorine; Dose-Response Relationship, Drug; Hospitalization; Humans; Hyponatremia; Male; Retrospective Studies; Sodium; Time Factors; Tolvaptan

2017
Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone.
    Journal of Korean medical science, 2018, Apr-09, Volume: 33, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Asian People; Benzazepines; Body Mass Index; Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Male; Middle Aged; Republic of Korea; Sodium; Tolvaptan; Treatment Outcome; Young Adult

2018
Impact of continued administration of tolvaptan on cirrhotic patients with ascites.
    BMC pharmacology & toxicology, 2018, Dec-18, Volume: 19, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Ammonia; Antidiuretic Hormone Receptor Antagonists; Ascites; Body Weight; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Serum Albumin; Tolvaptan; Treatment Outcome; Young Adult

2018
First experience with Tolvaptan for the treatment of neonates and infants with capillary leak syndrome after cardiac surgery.
    BMC pediatrics, 2019, 02-12, Volume: 19, Issue:1

    Topics: Airway Management; Antidiuretic Hormone Receptor Antagonists; Blood Transfusion; Body Weight; Capillary Leak Syndrome; Cardiac Surgical Procedures; Diuretics; Female; Fluid Therapy; Humans; Infant; Infant, Newborn; Liver; Male; Osmoregulation; Postoperative Complications; Retrospective Studies; Sodium; Tolvaptan; Urination

2019
Effects of tolvaptan on congestive heart failure complicated with chylothorax in a neonate.
    Pediatrics international : official journal of the Japan Pediatric Society, 2015, Volume: 57, Issue:5

    Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Chylothorax; Female; Heart Failure; Humans; Hyponatremia; Infant, Newborn; Male; Radiography, Thoracic; Tolvaptan; Transposition of Great Vessels

2015
[Preoperative Use of Tolvaptan in a Patient with Constrictive Pericarditis].
    Kyobu geka. The Japanese journal of thoracic surgery, 2016, Volume: 69, Issue:2

    Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Humans; Male; Pericarditis, Constrictive; Pleural Effusion; Preoperative Care; Tolvaptan; Tomography, X-Ray Computed

2016
A Safety and Efficacy Study of Tolvaptan Following Open Heart Surgery in 109 Cases.
    International heart journal, 2016, Jul-27, Volume: 57, Issue:4

    Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Cardiac Surgical Procedures; Female; Heart Failure; Humans; Male; Postoperative Care; Retrospective Studies; Tolvaptan; Treatment Outcome

2016
Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
    Cardiovascular drugs and therapy, 2011, Volume: 25 Suppl 1

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Atrial Natriuretic Factor; Benzazepines; Blood Pressure; Body Weight; Chlorides; Disease Models, Animal; Diuretics; Dogs; Furosemide; Heart Failure; Kidney; Male; Potassium; Renin; Sodium; Tolvaptan

2011
Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure.
    Journal of cardiology, 2012, Volume: 60, Issue:6

    Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Fluids; Body Weight; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Pulmonary Circulation; Sodium Chloride Symporter Inhibitors; Sodium Potassium Chloride Symporter Inhibitors; Time Factors; Tolvaptan; Urine; Vascular Resistance

2012
Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
    Biochemical pharmacology, 2008, Mar-15, Volume: 75, Issue:6

    Topics: Aldosterone; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Blood Pressure; Body Weight; Creatinine; Diuretics; Echocardiography; Furosemide; Heart Failure; Heart Rate; Male; Organ Size; Osmolar Concentration; Potassium; Rats; Rats, Inbred Lew; Renin; Sodium; Tolvaptan; Ventricular Remodeling

2008